Protocol Number: 07-M-0036

Title:

PET Imaging of Brain Amyloid Using [11C]MeS-IMPY

Number:

07-M-0036

Summary:

Alzheimer's disease is associated with accumulation in the brain of a protein called amyloid. The purpose of this study is to test the ability of a research drug to measure amyloid in brain using positron emission tomography (PET) and a research drug called [11C]MeS-IMPY.

Sponsoring Institute:

National Institute of Mental Health (NIMH)

Recruitment Detail

Type: Participants currently recruited/enrolled

Gender: Male & Female

Referral Letter Required: No

Population Exclusion(s): Children

Eligibility Criteria:

INCLUSION CRITERIA:

Healthy control subjects aged 18-90 years and AD patients aged 50-90, with history/physical exam, ECG, and laboratory tests.

Informed Consent.

AD Patients: Mini-Mental State Examination (score greater than or equal to 10).

AD Patients: Meet NINCDS-ADRDA criteria for probable AD.

EXCLUSION CRITERIA:

1. Current or prior history of any alcohol or drug abuse.

2. Severe systemic disease based on history and physical exam.

3. Positive result on urine screen for illicit drugs.

4. Laboratory tests with clinically significant abnormalities.

5. Prior participation in other research protocols or clinical care in the last year such that radiation exposure would exceed the annual limits.

6. Pregnancy or breast feeding.

7. Claustrophobia.

8. Presence of ferromagnetic metal in the body or heart pacemaker.

9. History of brain disease other than Alzheimer's disease.

10. Unable to lay on one's back for the PET/MRI scan.

Special Instructions:

Currently Not Provided

Keywords:

Alzheimer's Disease

Positron Emission Tomography

Brain

Neurochemistry

Beta-Amyloid Plaques

PET

MeS-IMPY

Recruitment Keyword(s):

Alzheimer Disease

AD

Dementia

Healthy Volunteer

HV

Condition(s):

Alzheimer's Disease

Healthy

Investigational Drug(s):

[11C]MeS-IMPY

Investigational Device(s):

None

Intervention(s):

Drug: [11C]MeS-IMPY

Supporting Site:

National Institute of Mental Health

Contact(s):

Patient Recruitment and Public Liaison Office
Building 61
10 Cloister Court
Bethesda, Maryland 20892-4754
Toll Free: 1-800-411-1222
TTY: 301-594-9774 (local),1-866-411-1010 (toll free)
Fax: 301-480-9793

Electronic Mail:prpl@mail.cc.nih.gov

Citation(s):

Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A, Cole GM, Small GW, Huang SC, Barrio JR. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci. 2001 Dec 15;21(24):RC189.

Burger C, Buck A. Requirements and implementation of a flexible kinetic modeling tool. J Nucl Med. 1997 Nov;38(11):1818-23.

Ichise M, Toyama H, Innis RB, Carson RE. Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab. 2002 Oct;22(10):1271-81.

• Questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.
• Technical questions regarding the Clinical Center web site, please contact the Department of Networks and Applications, CC.

Search The Studies | Help | Questions |
Clinical Center Home | NIH Home

National Institutes of Health Clinical Center Bethesda, Maryland 20892. Last update: 09/17/2008